Fundraising Fox
Orbit Genomics
Boulder, US · Delaware corporation · 8 employees on LinkedIn · 4 known investors
Find your way into Orbit Genomics
Each arrow is one introduction. Sign up to fill in the first one.
251 people can intro you to Dede
Ask Randy Berholtz to introduce you to Dede Willis
You →Randy · together at Orbit Genomics →Dede
Sign up to find every way you can get introduced to Orbit Genomics
- Your email: who you already know at Orbit Genomics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Orbit Genomics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Orbit Genomics is a precision healthcare company built on OrbiSeq, an AI-enabled genomics platform that analyzes short tandem repeats (STRs) alongside single nucleotide polymorphisms to detect disease biology. Its lead product is a blood test for diagnosing early-stage lung cancer in patients with indeterminate pulmonary nodules, with a pipeline extending across other therapeutic areas.
Founders & leadership
DW
Dede WillisCEO & Co-FounderWith over 25 years in life sciences leadership, she has managed the full product lifecycle—from development and clinical trials to launch and commercialization—across diagnostics, medical devices, and therapeutics in the US, Europe, and Asia.
OM
Oerum MikaelExecutive
E(
Elizabeth (Dede) N WillisExecutive
H(
Harold (Skip) GarnerNamed on SEC filing
Board
JS
Julie SilberBoard director
Investors · 4
Also in the syndicate · 2
New Horizon Health LtdleadNHH Ventureslead
Reported raises · per SEC filings
Form D private placements$780K disclosed across 1 of 2 rounds · 2022–2024
▶$780KraisedJul 2025 · 15 investors · BiotechnologyRule 506(b)
▶$780KraisedJul 2025 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Oerum MikaelDirector
- Harold (Skip) GarnerExecutive Officer, Director
- Elizabeth (Dede) N WillisExecutive Officer, Director
- Julie SilberDirector
- Offering amount
- $2M
- Amount sold
- $780K
- Minimum investment
- $5K
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 9
Polaris GenomicsPolaris Genomics is a Veteran-owned biotech startup mapping molecular biomarkers to develop objective, biologically-based diagnostics and novel therapeutics for mental health and neuropsychiatric conditions such as PTSD. It combines genomics and AI to advance precision mental health care.
Genomics PlcGenomics builds a genotype-phenotype database and genetic risk-prediction tools used to support pharmaceutical drug discovery and clinical trials, as well as population health management and clinical decision support for healthcare providers. It serves life sciences companies and healthcare systems through its Life Sciences and Health & Wellness divisions.
LabcorpLabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.
10X Genomics10x Genomics offers single cell analysis technology, including its Flex assay and Flex Apex product, which use probe-based chemistry and plate-based multiplexing to profile fresh, frozen, and FFPE samples for researchers. The tools support applications in cancer, immunology, and neuroscience, enabling gene expression and multiomic profiling of cell surface protein, intracellular protein, and CRISPR guides.
NeoGenomicsNeoGenomics develops diagnostic tests and tools for cancer care, including tests for immunotherapy response monitoring, therapy selection, and minimal residual disease detection.
HelixHelix is a population genomics company that provides an end-to-end platform to integrate genomic data into clinical care, research, and therapeutic development. It partners with health systems, providers, payers, life sciences organizations, and patients to enable genetic screening and personalized healthcare at scale.
Phase GenomicsPhase Genomics develops long-range genome sequencing technology based on proximity ligation, along with computational tools, for scientists studying cancer, inherited diseases, microbiomes, and biodiversity. It serves academic and research institutions and biopharmaceutical firms across life sciences, medicine, and agriculture.
IDbyDNAScalable, high throughput DNA sequencing platforms.
Arima GenomicsArima Genomics develops DNA-based cancer diagnostics that combine genomic sequence with 3D genome structural information (via Hi-C sequencing) to detect fusions, rearrangements, ecDNA, and other structural drivers of cancer. It serves clinicians and biopharma partners through its Aventa clinical testing brand and translational science collaborations, using routine FFPE tumor samples to guide diagnosis and therapy selection.
Companies working in the same space as Orbit Genomics.
Frequently asked questions
- What does Orbit Genomics do?
- Orbit Genomics is a precision healthcare company built on OrbiSeq, an AI-enabled genomics platform that analyzes short tandem repeats (STRs) alongside single nucleotide polymorphisms to detect disease biology. Its lead product is a blood test for diagnosing early-stage lung cancer in patients with indeterminate pulmonary nodules, with a pipeline extending across other therapeutic areas.
- Who founded Orbit Genomics?
- Orbit Genomics was founded by Dede Willis.
- Who are Orbit Genomics's investors?
- Orbit Genomics's investors include Rockies Venture Club, Ventac Partners.
- How much funding has Orbit Genomics raised?
- Orbit Genomics has disclosed $780K raised across 1 of its 2 known rounds.
- Where is Orbit Genomics headquartered?
- Orbit Genomics is headquartered in Boulder, US.